FDA Clears Automated Musculoskeletal Ultrasound Platform for Arthritis Assessment

In the United States, many counties lack rheumatology coverage, delaying objective imaging and consistent assessment. Standardized joint scanning remains difficult to scale across busy clinics. A newly cleared system now offers automated scan acquisition and AI-assisted analysis in an end-to-end workflow.

ROPCA (Odense, Denmark) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ARTHUR and DIANA, which together form a musculoskeletal ultrasound automation platform. ARTHUR, described as an Arthritis Ultrasound Robot, automatically captures ultrasound images of finger, hand, and wrist joints under healthcare-professional supervision. DIANA then analyzes the acquired images and supports automated report generation, while clinical decisions remain with clinicians.

Together, ARTHUR and DIANA deliver a streamlined workflow that combines consistent image acquisition, artificial intelligence-assisted interpretation, and structured reporting. ARTHUR has been CE-marked since 2022 and has several years of clinical experience across six European countries, including more than 5,400 scans and 83,500 joints. The platform is designed for specialist teams seeking reproducible assessments and operational consistency while maintaining existing clinical responsibilities.

FDA 510(k) clearance enables broader availability of the system to U.S. providers. The announcement comes amid capacity pressures in rheumatology, with cited data indicating that 72% of U.S. counties do not have a single rheumatologist and workforce projections pointing to a substantial supply-demand gap by 2030. With the clearance, the company can take the next step toward making ARTHUR and DIANA available to healthcare providers across the United States.

“FDA 510(k) clearance for ARTHUR & DIANA is a defining moment for ROPCA. ARTHUR, our Arthritis Ultrasound Robot, is designed to automatically capture ultrasound images of finger, hand, and wrist joints under healthcare-professional supervision – opening a new model for scalable musculoskeletal diagnostics. For providers, it can help address capacity and consistency; for patients, it points toward faster access to specialist assessment. We are now ready to build the U.S. clinical and commercial partnerships that take this new category forward,” said Johannes Schaeferhoff, CEO of ROPCA.

“ARTHUR brings something particularly valuable to rheumatology: the ability to obtain standardized, reproducible ultrasound assessments of joints autonomously and efficiently. As demand for rheumatologic care grows faster than our specialist workforce, technologies like ARTHUR have the potential to expand access to objective imaging, increase clinical capacity, and help rheumatologists deliver more efficient and consistent care to patients with inflammatory arthritis. At the Mayo Clinic, we have had the privilege to utilize this first-in-kind technology in the research space and look forward to the opportunity of bringing it into the clinical practice,” said Matthew J. Koster, MD, Associate Professor of Medicine, Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.

Related Links
ROPCA